The study addresses a growing problem in oncology. As people age, the immune system gradually loses some of its ability to recognize and eliminate abnormal cells, a process often described as immune aging or immunosenescence. This decline affects many components of immunity, including the activity of T cells that are essential for controlling cancer. Modern immunotherapies, such as immune checkpoint inhibitors, work by releasing inhibitory signals that restrain T cells. Yet removing those external brakes may not be enough when T cells have already been reshaped by an aged tumor microenvironment and have lost the internal capacity to expand or kill cancer cells efficiently. Understanding the biological causes of this dysfunction could help researchers design treatments specifically for older adults, who carry much of the global cancer burden.

The new work builds on earlier research by the Mass General Brigham team showing that aging changes the tumor microenvironment, the complex network of cancer cells, immune cells, blood vessels and signaling molecules surrounding a tumor. In older hosts, this environment can push CD8+ killer T cells toward a dysfunctional state. These cells may still reach the tumor and recognize malignant targets, but they become less capable of proliferating, surviving for long periods or releasing the toxic molecules needed to kill cancer cells. The researchers therefore focused on a central question: which genes inside T cells are responsible for this age-associated loss of function, and can disabling those genes restore antitumor activity?

To answer that question, the investigators performed a pooled CRISPR screen, a genetic technology that allows scientists to disrupt thousands of genes across a population of cells and then identify which alterations improve or weaken a desired biological response. Instead of examining one candidate gene at a time, the method creates a broad functional map of gene activity. The researchers conducted the screen in tumor-bearing aged mice, an experimental setting designed to capture the conditions encountered by T cells in older patients. The surviving and most effective T cells were then analyzed to determine which genetic changes helped them perform better within the aged tumor microenvironment.

The screen highlighted Dusp5 and Zfp219 as important regulators of separate aspects of T cell dysfunction. Dusp5, or dual specificity phosphatase 5, influences the ERK signaling pathway, a molecular cascade that helps T cells respond to stimulation and produce more copies of themselves. Signaling pathways function through a series of phosphorylation events, in which phosphate groups are added to proteins to alter their activity. Phosphatases remove those phosphate groups and can dampen the signal. In this case, the researchers found that Dusp5 acts as a brake on ERK signaling. Removing the gene allowed ERK activity to rise, helping T cells proliferate more effectively in the aged tumor environment.

The second gene, Zfp219, appeared to control the destructive machinery that T cells use against cancer. The gene encodes a zinc finger protein, a type of DNA-binding regulator that can influence whether particular genes are turned on or off. The researchers found that Zfp219 suppresses genes involved in the production of granzymes, enzymes stored and released by cytotoxic T cells. Granzymes, including granzyme A and granzyme B, enter targeted cells and activate molecular pathways that lead to cell death. When Zfp219 was knocked out, T cells increased their secretion of these tumor-killing proteins and became more effective at damaging malignant cells.

Together, the results suggest that immune aging does not weaken cancer immunity through a single universal mechanism. Instead, it can interfere with several distinct biological programs at once. One pathway limits the ability of T cells to expand, while another restricts the production of molecules required for direct tumor killing. This division of labor may be important for future therapies, because simply increasing the number of T cells in a tumor will not necessarily improve treatment if those cells remain unable to destroy cancer cells. Conversely, boosting cytotoxic activity may have limited impact if the cells cannot persist or reproduce. The two genes identified in the study therefore represent complementary targets for improving both the quantity and quality of the antitumor response.

The researchers also examined whether their findings were relevant to human cancer. They found that older adults had higher levels of ZNF219 in T cells located within their tumors. Increased expression of the gene was associated with poorer responses to immune checkpoint blockade and shorter survival. These observations do not prove that ZNF219 directly causes treatment resistance or poor outcomes, but they suggest that the gene could become an age-related prognostic marker. Measuring ZNF219 activity in tumor-infiltrating T cells might eventually help clinicians estimate how effectively a patient’s immune system is likely to respond to checkpoint therapy. Such a test would require validation in larger, diverse patient groups and across multiple cancer types before it could be used routinely.

Directly targeting ZNF219 with a conventional drug may be difficult because the protein functions as a gene-regulating factor rather than an easily accessible enzyme. The researchers point to engineered T cell therapies as one possible route around that challenge. In approaches such as CAR-T cell therapy, a patient’s T cells are collected, genetically modified in the laboratory and returned to the body after expansion. In principle, these cells could be engineered to reduce or eliminate ZNF219 activity before infusion. Similar strategies might be incorporated into other forms of adoptive cell therapy, potentially creating T cells with stronger granzyme production and greater resistance to the suppressive conditions found in older tumors.

The work remains a preclinical advance rather than an immediately available treatment. The safety of altering Dusp5 or ZNF219 must be carefully assessed, since excessive T cell activation can cause tissue damage, autoimmune reactions or dangerous inflammatory responses. Researchers will also need to determine whether the benefits observed in aged mice can be reproduced in human tumors, which differ widely in their genetics, immune composition and response to therapy. Even so, the study offers a detailed molecular explanation for one facet of immune aging and identifies targets that may be especially relevant to older cancer patients. By showing that age-related T cell dysfunction can be dissected genetically—and potentially reversed—the findings could help move cancer immunotherapy toward treatments designed not only for the tumor type, but also for the biological age of the immune system.

Subject of Research: Age-related T cell dysfunction in cancer and genetic targets for restoring antitumor immunity

Article Title: CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer

Web References: https://www.massgeneralbrigham.org/en/patient-care/services-and-specialties/cancer ; https://www.nature.com/articles/s41590-024-01828-7 ; https://www.cell.com/cell/abstract/S0092-8674(26)00814-7

References: Chen, ACY, et al. “CRISPR screens identify targets to rescue age-related T cell dysfunction in cancer.” Cell. DOI: 10.1016/j.cell.2026.07.016

Keywords: cancer immunotherapy, immune aging, T cells, CD8+ T cells, CRISPR screening, Dusp5, Zfp219, ZNF219, tumor microenvironment, immune checkpoint blockade, granzymes, CAR-T therapy, cancer prognosis

Colorectal cancer cells are known to harbor elevated iron concentrations, far surpassing those found in healthy cells. Iron is a double-edged sword in cellular physiology—essential for processes like DNA synthesis and cell proliferation but lethal in excess due to its propensity to generate harmful reactive oxygen species. Ordinarily, cells with excessive iron succumb to ferroptosis, a specialized form of oxidative cell death driven by iron-mediated lipid peroxidation. Tumor cells subvert this natural safeguard, sustaining iron overload without triggering their own demise, but how they achieve this has remained elusive—until now.

The investigative team led by Dr. Yatrik Shah, Horace W. Davenport Collegiate Professor of Physiology at Michigan Medicine, employed a metabolism-directed CRISPR screening approach to systematically dissect the pathways protecting colorectal cancer cells from iron-induced oxidative damage. Surprisingly, canonical ferroptotic enzymes, previously presumed central to this resistance, were found non-essential for tumor survival. This redirected focus led the scientists to explore mitochondrial metabolism more profoundly.

Their research unveiled that the mitochondrial enzyme complex II plays a pivotal role in safeguarding cancer cells from iron-induced toxicity. Complex II regulates coenzyme Q (CoQ) within mitochondria, a key antioxidant molecule that quells oxidative stress. By fine-tuning CoQ’s redox state, complex II effectively buffers the destructive potential of accumulated iron, preventing ferroptosis and enabling cancer cell proliferation. When researchers knocked out complex II in colorectal cancer models, iron toxicity became unmanageable for the tumor cells, leading to widespread cell death and marked tumor growth inhibition.

Crucially, complex II’s protective mechanism appears specific to the high-iron environment of cancer cells. In mouse models, disruption of complex II elicited negligible adverse effects on normal tissues, underscoring the therapeutic potential of selectively targeting this mitochondrial axis in colorectal cancer. This specificity addresses a significant hurdle in oncology: minimizing treatment toxicity while maximizing antitumor efficacy.

Further intricacies emerged as the study revealed a feedback loop wherein iron itself modulates complex II activity, suggesting a sophisticated regulatory axis that maintains iron homeostasis within tumors. This bidirectional interaction offers additional molecular targets for disrupting iron tolerance in cancer cells and deepening our understanding of tumor metabolism.

These findings represent a paradigm shift from earlier hypotheses centered on canonical ferroptosis regulators, highlighting the necessity of focusing on mitochondrial metabolism in cancer research. By leveraging sophisticated genome-editing tools and bioenergetic profiling, the Rogel Cancer Center team charted a novel course for drug discovery efforts aimed at crippling iron addiction—a hallmark of not only colorectal but potentially many other malignancies.

The next phase of this research endeavors to identify and develop potent inhibitors of complex II or its associated metabolic pathways. Given that dysregulated iron metabolism is a common vulnerability across diverse cancer types, these interventions could herald a new era of broad-spectrum anticancer strategies. Moreover, detailed characterization of iron complex II interplay might uncover additional metabolic dependencies exploitable for therapeutic gains.

This transformative research underscores the intricate metabolic adaptations that empower colorectal cancers to circumvent intrinsic iron toxicity constraints. By illuminating the heme-complex II axis as a linchpin in maintaining oxidative balance amid iron overload, it offers a highly selective target for the design of next-generation anticancer agents.

Researchers anticipate that combining complex II inhibition with other therapies may amplify treatment responses and overcome resistance mechanisms. As the quest to outsmart cancer evolves, this study reinforces the vital role of mitochondrial metabolism understanding in crafting innovative clinical interventions.

In sum, the University of Michigan team’s discovery of complex II’s role in buffering iron toxicity not only deciphers a long-standing biological enigma but also charts a compelling translational pathway. It epitomizes how fundamental metabolic insights can accelerate the development of precision treatments conferring hope to millions affected by colorectal cancer worldwide.

Subject of Research: Cells
Article Title: Iron addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death
News Publication Date: June 17, 2026
Web References: http://dx.doi.org/10.1016/j.cmet.2026.04.020
References: “Iron addicted colorectal cancers exploit heme-complex II axis to resist oxidative cell death,” Cell Metabolism, DOI: 10.1016/j.cmet.2026.04.020
Image Credits: Shah Lab, Rogel Cancer Center
Keywords: Colorectal cancer, iron metabolism, ferroptosis, complex II, coenzyme Q, mitochondrial metabolism, oxidative cell death, tumor metabolism, cancer therapy